[go: up one dir, main page]

NO2119726T3 - - Google Patents

Info

Publication number
NO2119726T3
NO2119726T3 NO08008944A NO08008944A NO2119726T3 NO 2119726 T3 NO2119726 T3 NO 2119726T3 NO 08008944 A NO08008944 A NO 08008944A NO 08008944 A NO08008944 A NO 08008944A NO 2119726 T3 NO2119726 T3 NO 2119726T3
Authority
NO
Norway
Application number
NO08008944A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39789337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2119726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2119726T3 publication Critical patent/NO2119726T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO08008944A 2008-05-14 2008-05-14 NO2119726T3 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08008944.4A EP2119726B2 (en) 2008-05-14 2008-05-14 Novel and powerful MHC-class II peptides derived from survivin and neurocan

Publications (1)

Publication Number Publication Date
NO2119726T3 true NO2119726T3 (ja) 2015-05-23

Family

ID=39789337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08008944A NO2119726T3 (ja) 2008-05-14 2008-05-14

Country Status (24)

Country Link
US (5) US8647629B2 (ja)
EP (3) EP2119726B2 (ja)
JP (1) JP5663473B2 (ja)
KR (2) KR101602024B1 (ja)
CN (1) CN102027006B (ja)
AU (1) AU2009248413B2 (ja)
BR (2) BRPI0912622A2 (ja)
CA (1) CA2724198C (ja)
CY (2) CY1115999T1 (ja)
DK (2) DK2119726T5 (ja)
EA (1) EA019603B1 (ja)
ES (2) ES2532896T5 (ja)
HK (2) HK1156323A1 (ja)
HR (2) HRP20150300T4 (ja)
HU (2) HUE024541T2 (ja)
MX (1) MX2010012443A (ja)
NO (1) NO2119726T3 (ja)
NZ (1) NZ588605A (ja)
PL (2) PL2119726T5 (ja)
PT (2) PT2119726E (ja)
RS (1) RS53872B2 (ja)
SI (2) SI2119726T2 (ja)
UA (1) UA103481C2 (ja)
WO (1) WO2009138236A1 (ja)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
KR101167392B1 (ko) * 2007-07-27 2012-07-19 이매틱스 바이오테크놀로지스 게엠베하 종양 관련 펩티드의 조성물 및 관련된 항암 백신
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
DK2119726T5 (en) * 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012023033A2 (en) * 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
KR20130126671A (ko) * 2010-12-14 2013-11-20 이매틱스 바이오테크놀로지스 게엠베하 전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법
CN102181401B (zh) * 2011-02-01 2013-04-24 北京市肿瘤防治研究所 存活素酶联免疫试剂盒及其应用
CN103961307B (zh) * 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
WO2015066057A2 (en) * 2013-10-28 2015-05-07 Baylor College Of Medicine Expansion of cmv-specific t cells from cmv-seronegative donors
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
WO2016079114A1 (en) 2014-11-18 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Novel polymeric hgh prodrugs
EP3988083A1 (en) 2014-11-21 2022-04-27 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
ES2970246T3 (es) * 2015-03-27 2024-05-27 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
IL308735A (en) * 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MY188354A (en) * 2015-07-06 2021-12-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MY198087A (en) * 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
MY196837A (en) * 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CN109715788A (zh) * 2016-06-28 2019-05-03 金纽斯生物科技公司 用于免疫疗法的t细胞组合物
IL265479B (en) 2016-09-21 2022-09-01 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
RS64217B1 (sr) 2017-01-27 2023-06-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jajnika i drugih malignih tumora
EA201991444A1 (ru) * 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
CA3054866A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Personalised immunogenic peptide identification platform
EP3648790A1 (en) * 2017-07-07 2020-05-13 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
US10800823B2 (en) * 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US20200256877A1 (en) 2017-10-09 2020-08-13 Enterome S.A. Microbiota Sequence Variants Of Tumor-Related Antigenic Epitopes
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
US12036257B2 (en) 2017-10-31 2024-07-16 Kalivir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
RS63873B1 (sr) 2018-04-11 2023-02-28 Enterome S A Antigenski peptidi za prevenciju i lečenje raka
AU2019268411B2 (en) * 2018-05-15 2024-03-14 Interk Peptide Therapeutics Limited Activating agents
US11912789B2 (en) * 2018-05-15 2024-02-27 Interk Peptide Therapeutics Limited Peptide activating agent
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
EP4045150A1 (en) 2019-10-16 2022-08-24 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
HUE065075T2 (hu) 2019-11-15 2024-04-28 Enterome S A Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére
MX2022012758A (es) * 2020-04-14 2022-11-30 Univ Montreal Novedosos antigenos especificos de tumores para leucemia mieloide aguda (aml) y usos de estos.
JP2022144748A (ja) * 2021-03-19 2022-10-03 日本電気株式会社 検査システム及び検査方法
CA3215344A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
CA3229551A1 (en) * 2021-08-17 2023-02-23 Intomics A/S Vaccine design pipeline
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
NZ192465A (en) 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5733742A (en) 1993-06-03 1998-03-31 Therapeutic Antibodies Inc. Production of antibody fragments from whole blood
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US6274362B1 (en) * 1999-02-04 2001-08-14 Millennium Pharmaceuticals, Inc. RGS-containing molecules and uses thereof
CA2404489A1 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002353289A1 (en) 2001-12-13 2003-06-23 Koninklijke Philips Electronics N.V. Recommending media content on a media system
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
CN1691964A (zh) * 2002-09-06 2005-11-02 曼康公司 表位序列
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7811828B2 (en) * 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
DK1760089T3 (da) 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
ATE461214T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
AU2006311538A1 (en) † 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
KR101167392B1 (ko) * 2007-07-27 2012-07-19 이매틱스 바이오테크놀로지스 게엠베하 종양 관련 펩티드의 조성물 및 관련된 항암 백신
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
DK2119726T5 (en) † 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka

Also Published As

Publication number Publication date
CY1117171T1 (el) 2017-04-05
US20200078439A1 (en) 2020-03-12
BRPI0912622A2 (pt) 2016-05-03
JP5663473B2 (ja) 2015-02-04
CN102027006B (zh) 2016-01-13
EA201071297A1 (ru) 2011-04-29
PT2119726E (pt) 2015-03-30
DK2119726T3 (en) 2015-02-16
US10434136B2 (en) 2019-10-08
US20140127242A1 (en) 2014-05-08
US20140086943A1 (en) 2014-03-27
KR101602024B1 (ko) 2016-03-09
HRP20150300T1 (hr) 2015-04-24
RS53872B2 (sr) 2018-06-29
HUE024541T2 (hu) 2016-01-28
PL2291395T5 (pl) 2019-04-30
KR101509284B1 (ko) 2015-04-10
DK2119726T4 (en) 2018-02-19
HK1209757A1 (en) 2016-04-08
EP2899206A1 (en) 2015-07-29
EP2291395B1 (en) 2015-08-12
AU2009248413B2 (en) 2014-07-17
PL2119726T5 (pl) 2018-04-30
EP2119726B1 (en) 2014-12-24
US8647629B2 (en) 2014-02-11
SI2119726T2 (en) 2018-03-30
HRP20151135T1 (hr) 2015-11-20
AU2009248413A1 (en) 2009-11-19
WO2009138236A1 (en) 2009-11-19
US9498512B2 (en) 2016-11-22
DK2291395T3 (da) 2015-09-21
BR122019014468B8 (pt) 2021-07-27
CA2724198A1 (en) 2009-11-19
CA2724198C (en) 2016-03-22
EA019603B1 (ru) 2014-04-30
DK2119726T5 (en) 2018-03-26
PL2291395T3 (pl) 2016-01-29
HRP20150300T4 (hr) 2018-03-09
HUE028102T2 (en) 2016-11-28
HRP20151135T4 (hr) 2019-03-08
ES2549088T3 (es) 2015-10-22
ES2549088T5 (es) 2019-04-29
EP2119726B2 (en) 2017-11-29
SI2291395T2 (sl) 2019-03-29
RS53872B1 (en) 2015-08-31
CY1115999T1 (el) 2017-01-25
PL2119726T3 (pl) 2015-05-29
BR122019014468B1 (pt) 2020-09-15
HK1156323A1 (en) 2012-06-08
SI2119726T1 (sl) 2015-05-29
US20100029571A1 (en) 2010-02-04
PT2291395E (pt) 2015-10-23
NZ588605A (en) 2012-06-29
CN102027006A (zh) 2011-04-20
ES2532896T3 (es) 2015-04-01
EP2119726A1 (en) 2009-11-18
US20130323272A1 (en) 2013-12-05
EP2291395B2 (en) 2018-11-14
SI2291395T1 (sl) 2015-10-30
MX2010012443A (es) 2010-12-20
ES2532896T5 (es) 2018-03-20
EP2291395A1 (en) 2011-03-09
KR20130041375A (ko) 2013-04-24
JP2011520436A (ja) 2011-07-21
US11957729B2 (en) 2024-04-16
DK2291395T4 (en) 2019-02-18
UA103481C2 (ru) 2013-10-25
KR20110021881A (ko) 2011-03-04

Similar Documents

Publication Publication Date Title
BR112016019572A2 (ja)
BRPI0908549B8 (ja)
NO2119726T3 (ja)
BRPI0920750A2 (ja)
BRPI0922455A2 (ja)
BRPI0907698A2 (ja)
BRPI0923734A2 (ja)
BRPI0912727A2 (ja)
BRPI0922669A2 (ja)
BRPI0908285A2 (ja)
BRPI0910485A2 (ja)
BRPI0914750A2 (ja)
BRPI0919811A2 (ja)
BRPI0908120A2 (ja)
BRPI0904541A8 (ja)
BRPI0920914A2 (ja)
BRPI0922550A2 (ja)
BRPI0913605A2 (ja)
CH2347250H2 (ja)
BRPI0914820A2 (ja)
AR073287B1 (ja)
BRPI0919477A2 (ja)
BRPI0923127A (ja)
BRPI0923137A2 (ja)
BRMU8803485U8 (ja)